期刊文献+

Effects of Interferon Alpha 2b on VEGFR-2, VEGFA, MAPK-1 and ERK-1 Gene Expression in Corneal Neovascularization Models

Effects of Interferon Alpha 2b on VEGFR-2, VEGFA, MAPK-1 and ERK-1 Gene Expression in Corneal Neovascularization Models
下载PDF
导出
摘要 AIM: To investigate effects of interferon alpha 2b on vascular endothelial growth factor receptor-2 (VEGFR-2), vascular endothelial growth factor-A (VEGFA), mitogen activated protein kinase-1 (MAPK-1) and extracellular signal regulated kinase (ERK 1) gene expression in corneal neovascularization (CNV) modelsbyreal time polymerase chain reaction (PCR). METHODS: Thirty Wistar-Albino male rats were divided into three groups of ten rats each, and two corneas were obtained from each rat. CNV was induced by application of silver nitrate. In the first group one million IU/ml, in the second group three million IU/ml interferon-alfa 2b and in the third (control) group isotonic saline was applied to both eyes two times a day for two weeks. Rats were sacrificed by cervical dislocation and corneas were used for real time polymerase chain reaction. RESULTS: MAPK-1 gene expression levels were significantly higher in both first and second groups compared to the control group (p = 0.014 and p = 0.008, respectively). VEGFR-2 gene expression levels were found to be significantly higher in the second group than the control group (p = 0.028). VEGFA gene expression levels were also significantly higher in the second group than the control group, and there was no difference between the control and first group and between first and second groups (p > 0.05). ERK gene expression levels did not differ among all groups (p = 0.545). CONCLUSION: At the end of the study, it was shown that interferon-alfa 2b does not inhibit VEGFR-2, VEGFA, MAPK-1 or ERK 1 gene expression in CNV models despite its known anti-VEGF activities. AIM: To investigate effects of interferon alpha 2b on vascular endothelial growth factor receptor-2 (VEGFR-2), vascular endothelial growth factor-A (VEGFA), mitogen activated protein kinase-1 (MAPK-1) and extracellular signal regulated kinase (ERK 1) gene expression in corneal neovascularization (CNV) modelsbyreal time polymerase chain reaction (PCR). METHODS: Thirty Wistar-Albino male rats were divided into three groups of ten rats each, and two corneas were obtained from each rat. CNV was induced by application of silver nitrate. In the first group one million IU/ml, in the second group three million IU/ml interferon-alfa 2b and in the third (control) group isotonic saline was applied to both eyes two times a day for two weeks. Rats were sacrificed by cervical dislocation and corneas were used for real time polymerase chain reaction. RESULTS: MAPK-1 gene expression levels were significantly higher in both first and second groups compared to the control group (p = 0.014 and p = 0.008, respectively). VEGFR-2 gene expression levels were found to be significantly higher in the second group than the control group (p = 0.028). VEGFA gene expression levels were also significantly higher in the second group than the control group, and there was no difference between the control and first group and between first and second groups (p > 0.05). ERK gene expression levels did not differ among all groups (p = 0.545). CONCLUSION: At the end of the study, it was shown that interferon-alfa 2b does not inhibit VEGFR-2, VEGFA, MAPK-1 or ERK 1 gene expression in CNV models despite its known anti-VEGF activities.
出处 《Open Journal of Ophthalmology》 2018年第2期97-105,共9页 眼科学期刊(英文)
关键词 Corneal NEOVASCULARIZATION Vascular Endothelial Growth Factor Interferon-Alfa2b Real Time POLYMERASE Chain Reaction Corneal Neovascularization Vascular Endothelial Growth Factor Interferon-Alfa2b Real Time Polymerase Chain Reaction
  • 相关文献

参考文献1

二级参考文献83

  • 1Hosseini H, Nowroozzadeh MH, Salouti R, Nejabat M. Anti- vegf therapy with bevacizumab for anterior segment eye disease. Cornea 2012, 31: 322-334.
  • 2Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clinic proceedings.Mayo Clinic 2012, 87: 77-88.
  • 3Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007, 18: 502-508.
  • 4Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006, 26: 859-870.
  • 5Miller JW. Vascular endothelial growth factor and ocular neovascularization. American J Pathol 1997, 151 : 13-23.
  • 6Keane PA, Sadda SR. Development of anti-vegf therapies for intraocular use: A guide for clinicians. J Ophthalmol 2012, 2012: 483034.
  • 7Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med 2010, 16: 1107-1111.
  • 8Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991, 266:11947-11954.
  • 9Ferrara N, Gerber HP, LeCouter J. The biology of vegf and its receptors. Nat Med 2003, 9: 669-676.
  • 10Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AE Pegaptanib, a targeted anti-vegf aptamer for ocular vascular disease. Nature Rev. Drug discovery 2006, 5: 123-132.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部